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Abstract. Background/Aim: Although insulin-like growth
factor-1 (IGF-1) is well-implicated in cancer biology, the
potential roles of IGF-1 variants in different types of cancer
are largely unknown. The aim of the present study was to in
vitro characterize several human cancers for their IGF-1
variant expression patterns. Materials and Methods: Using
a novel quantitative real-time polymerase chain reaction
(qRT-PCR) assay, twelve human cancer cell lines were
investigated for their endogenous expression levels of IGF-1
variants, including classes. Additionally, the hormonal
regulation of IGF-1 transcripts was investigated in PC3
cells. Results: IGF-1Ea and Eb were found at higher levels
in KLE and MEL28 cells, respectively. MCF7 had the lowest
expression of Ec peptide and, along with MB231, lacked
IGF-1Eb. In most cases, class 1 proved as the predominant
origin. Estradiol (E2) or dexamethasone (Dexa) significantly
modulated IGF-1Ea and IGF-1Eb and down-regulated the
Ec peptide in PC3. Conclusion: Our results contribute to the
notion of distinct roles of IGF-1 isoforms in human cancer
depending on the type of malignancy.
The insulin-like growth factor-1 (IGF-1) is a potent mitogenof major importance in human physiology and developmentwith numerous proliferative and anti-apoptotic effectsaddressed (1). The 100kb IGF-1 gene is located on the longarm of chromosome 12 (12q22-12q24) and it consists of 6exons (2, 3). Combination of different transcription initiationsites, alternative splicing at both 5’ and 3’ ends and post-translational modifications, such as proteolytic processingand glycosylation events, give rise to multiple products
(isoforms) (4). More specifically, the precursor IGF-1polypeptides consist of the signal peptide, mature IGF-1 andthe E peptides; mature IGF-1 is a single-chain 70-amino-acid(aa)-peptide consisting of exons 3 and 4, while at thecarboxyl (C)-terminal, extension of the pro-IGF-1 peptidesand combination of exons 5 and 6 results in distinct Epeptides, named Ea, Eb and Ec. Thus, alternative splicing,containing only exon 5, results in the IGF-1Eb isoform,whereas containing exon 6 but excluding exon 5 results inIGF-1Ea (5). A third variant, the IGF-1Ec, is also generatedby alternative splicing in the human IGF-1 gene and containsboth exons 5 and 6 (6). At the N-terminal, usage of differentpromoters, located either in exon 1 or 2 produces class 1 orclass 2 IGF-1 molecules, respectively. Pro-IGF-1 peptidesconsist of mature and E peptides (4) (Figure 1A). Although over the last decade an increasing number ofstudies indicate a differential association of IGF-1 isoformswith several pathophysiological processes, such asmyocardium remodeling, skeletal muscle regeneration andendometriosis (7-9), the potentially distinct molecularfunctions of IGF-1 E peptides, and especially of its differentclasses, are largely unknown. Interestingly, over the lastyears, focus has turned into clarifying the role of specificIGF-1 isoforms in cancer biology (9-12). The differentialexpression pattern of IGF-1 isoforms observed in in vitromodels, indicate a unique and distinct role of pro-peptides indifferent cancer types including osteosarcoma, prostate,endometrial and cervical malignancies (10–12). However,less is known about the possibly specific roles of the IGF-1isoforms or, particularly, of its different classes in the varioustypes of cancer.Against this background, the aim of the present study wasto characterize several immortalized cell lines, the majority ofwhich served as models of numerous human cancer types,regarding their expression pattern of IGF-1 isoforms at themRNA level, including their classes, under control and/orhormonal conditions. Twelve cell lines were used simulating,among others, breast, hepatocellular, lung, melanoma and colonmalignancies. The results presented herein indicate for the firsttime the distinct identification of IGF-1 transcripts in so many
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malignant tissue culture models, further supporting the notionfor differential and unique roles of IGF-1 isoforms in humancancer biology, depending on the type of malignancy. 
Materials and Methods
Primer design. All primer sets designed de novo, for increasedefficiency and specificity, to be complementary to the unique exonscorresponding to each IGF-1 transcript (Figure 1A) and within thecoding region using the sequencing provided by the National Centerfor Biotechnology Information (NCBI), while their specificity waschecked using the NCBI Primer BLAST tool. Forward primers forpro- and class 1 or 2 IGF-1 peptides were common for all primersets and located to exon 4 and 1 or 2-3 (junction) exons,respectively, while reverse primers for pro-IGF1-Ea and -Eb werelocated to exons 4-6 (junction) and 5, respectively. Amplification ofthe IGF-1Ec transcript corresponding to the last (C-terminal) 24 aaof bioactive protein (Ec peptide) was achieved using a primer’s paircomplementary to exon 5 (sense) and exon 6 (antisense) (Table I,Figure 1A). Efficiency of all primer’s sets was validated beforetested to cells using serial dilutions in cDNA obtained from humanmuscle tissue, which served as positive control. All sets were foundto have acceptable efficiencies, between 90 and 120% (Figure 2A),and unique curve picks in predicted for their length and GC contentmelting temperature, as shown in melting curve analysis (Figure3A-I) in the same cycling conditions. Both sequencing (not shown)and electrophoretic analysis of the real-time PCR products inagarose gel (e.g., Ec peptide is shown, in Figure 2B) further verifiedthe specificity of each target transcript. Although all primer setswere designed to correspond to intron-exon spanning regions or toexon-exon junctions (Figure 1A and B), they were checked for theircontaminating DNA amplification potential in a boosted PCR
reaction of 45 cycles using 300 ng of genomic DNA as template.The resulting PCR product was further analyzed in agarose gelelectrophoresis where no bands were observed (Figure 2C). Primersdesigned for amplification of genomic sequence of cyclophilin wereused as positive control of the reaction.
Cell cultures and treatments. The following employed normal andcancerous human cell lines were obtained from the American TypeCulture Collection (ATCC, Bathesda, MD, USA): normal lensepithelial (HLE-B3), androgen sensitive prostate adenocarcinoma(LnCaP), androgen negative prostate cancer (PC3), estrogen positivebreast adenocarcinoma (MCF7), estrogen negative breastadenocarcinoma (MDA-MB-231), hepatocellular carcinoma (HuH7),normal kidney (HEK293), endometrial cancer (KLE), epithelialcervical cancer (HeLa), lung cancer (A549), melanoma (SK-MEL28), osteosarcoma (MG63) and colon cancer cells (DLD1). Allcell lines were cultured in selective growth medium supplementedwith 10-20% fetal bovine serum (FBS) and/or 2mM L-glutamine(Lonza, Basel, Switzerland) according to ATCC instructions and 1%penicilin/streptomycin (GIBCO, Life Technologies, Grand Island,NY, USA) and maintained in an tissue culture incubator at 37o C and5% CO2. At control conditions, cells reached confluence ofapproximately 80% before harvesting. Adherent cells were washedtwice with phosphate buffer salina (PBS) prior to trypsinization(GIBCO). Estradiol (E2), Dexamethasone (Dexa) and GrowthHormone (GH) (Sigma-Aldrich, St. Louis, MO) were selected astreatment factors and used in concentrations of 1, 10, 25 and 100 nΜfor 24 and 48 h in a dose- and time-response manner respectively. 
RNA extraction and cDNA synthesis. Total RNA was extracted fromcells using the TRI reagent RT-111 (RT-111; MRC Inc., Cincinnati,OH, USA) according to manufacturer’s instructions. RNAconcentration was photometricaly measured using the optical density
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Table I. Sequences of oligonucleotides used for amplification and quantification of the distinct IGF-1 variants in the qRT-PCR assay and the resulting
products’ length.
IGF-1 variant Primer pair (exon location and DNA strand) Sequences (5’-3’) Product length (bp)
Ea IGF-1 exon 4 sense GTATTGCGCACCCCTCAAG 94IGF-1 Ea exon 4-6 anti-sense CAAATGTACTTCCTTCTGGGTC 94Eb IGF-1 exon 4 sense GTATTGCGCACCCCTCAAG 234IGF-1 Eb exon 5 anti-sense CTACTTCCAATCTCCCTCCTCTG 234Ec peptide Ec peptide exon 5 sense GTTTCTTATCAGCCCCCATCTACCA 87Ec peptide exon 6 anti-sense GTTTCTCTACTTGCGTTCTTCAAATGTAC 87Class 1 Ea Class 1 exon 1 sense ATCAGCAGTCTTCCAACCCA 405IGF-1 Ea exon 4-6 anti-sense CAAATGTACTTCCTTCTGGGTC 405Class 1 Eb Class 1 exon 1 sense ATCAGCAGTCTTCCAACCCA 545IGF-1 Eb exon 5 anti-sense CTACTTCCAATCTCCCTCCTCTG 545Class 1 Ec peptide Class 1 exon 1 sense ATCAGCAGTCTTCCAACCCA 468Ec peptide exon 6 anti-sense CTACTTGCGTTCTTCAAATGTAC 468Class 2 Ea Class 2 exon 2 sense ATGATTACACCTACAGTGAAGATG 366IGF-1 Ea exon 4-6 anti-sense CAAATGTACTTCCTTCTGGGTC 366Class 2 Eb Class 2 exon 2 sense ATGATTACACCTACAGTGAAGATG 506IGF-1 Eb exon 5 anti-sense CTACTTCCAATCTCCCTCCTCTG 506Class 2 Ec peptide Class 2 exon 2 sense ATGATTACACCTACAGTGAAGATG 429Ec peptide exon 6 anti-sense CTACTTGCGTTCTTCAAATGTAC 429
IGF-1, Insulin-like growth factor-1; qRT-PCR: quantitative reverse transcription-polymerase chain reaction.
absorbance at 260 nm in a nano-drop spectophotometer, whereas theabsorbance ratio at 260/280 nm and the identification of 18s and 28sbands in 1% agarose gels after RNA electrophoresis were used toevaluate the quality of extracted RNAs (not shown). Following DNasetreatment (Invitrogen, Life Technologies, Grand Island, NY, USA) onemicrogram (1 μg) of each RNA were processed to cDNA synthesisusing 0.5 μg oligo DT primers (Fermentas, GmbH, Germany), 0.5 mMdNTPs (HT Biotechnology, Cambridge, UK), 200 U of M-MuLVreverse transcriptase (Finnzymes, Thermo Fisher Scientific, PittsburghPA, USA) and 4 U ribonuclease inhibitor (Qiagen, Valencia, CA,USA) according to manufacturer’s instructions.
Quantitative reverse transcription real-time PCR. Equal amounts(20 ng) of the obtained cDNAs were further quantified for theexpression of IGF-1 isoforms using 0.4 μΜ of each primer setdescribed above and 1x Kapa SYBR FAST qPCR kit (KAPABiosystems, Wilmington, MA, USA) in the same cycling conditions(95˚C for 30 s, 95˚C for 3 s, 63˚C for 30 s, for 40 cycles) for alltranscripts tested. The levels of the different variants of transcripts
were assessed by calculating the threshold cycle (Ct) as the numberof cycles at which the measured fluorescence exceeded the thresholdfor detection, which was automatically set by the Bio-Rad iQ5 Real-Time PCR Detection System (Hercules, CA, USA) software. Eachsample was analyzed in triplicate and the resulting data wereaveraged. A melting curve (Tm) analysis was also generated by thesystem’s software following the final cycle (40) for eachexperimental sample by continuous monitoring the SYBR greenfluorescence throughout the temperature ramp from 65˚ to 95˚C.QPCR products were verified after both melting curve analysis andagarose gel electophoresis prior to relative quantification. Relativedifferences between IGF-1 variant expressions after hormonaltreatments and control conditions in PC3 cells were estimated asfold changes using the ddCT method. Differences in expressionlevels of IGF-1 isoforms within cell lines used were performed bycomparing the mean±standard deviation (SD) of individualdifference between threshold cycle values (dCT). In all cases β-actin(FWD: CCTCGCCTTTGCCGA , RVS: TGGTGCCTGGGGCG)served as an internal control.
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Figure 1. Schematic representation of IGF-1 alternative splicing peptides. Mature IGF-1 consists of exons 3 and 4. At the N-terminal the signal
peptides consist of exon 1 or 2 spliced with part of exon 3 and give rise to class 1 or 2 molecules, respectively, whereas at the C-terminal
combinations of exon 4 with exon 5 or 6 or both produce the E peptides named Ea, Eb and Ec. Primers used for amplification of alternative IGF-
1 transcripts are marked as arrows and are located in their designed complementary exon or exon-exon junction. Forward (sense) primers are
presented as right (clockwise) blue arrows, whereas reverse (antisense) primers as left (reverse clockwise) brown arrows (A). The intron-exon
spanning or exon-exon junction design of primers and the length of intervening introns (B) eliminates the possibilities of contaminating DNA
amplification. IGF-1, Insulin-like growth factor-1.
Statistical analysis. Unpaired t-test and/or regression analysis wereused for the fold changes or the dCTs values given and a p-value<0.05 was considered as significant.
Results
Identification of distinct IGF-1 isoform expression patterns
unique for each cell line under control conditions. Cell lineswere cultured under their individual suggested control
conditions and examined for their mRNA levels of IGF-1isoforms as described in Materials and Methods. Thecharacterization of several human cancer cell linesconcerning the expression pattern of IGF-1 Pro- and E-peptides is shown in Figure 4A. More specifically, the KLEand SK-MEL28 cell lines were found to have the maximumexpression of pro-IGF1-Ea and -Eb peptides, respectively.Additionally, KLE and MEL28 cells, along with DLD1 and
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Figure 2. Efficiencies and specificity of primers used for quantification of IGF-1 variants. Efficiency of primers’ amplification used in the qRT-PCR
assay was checked using serial dilutions of cDNA obtained from human muscle tissue and was calculated from the slopes of standard curves. All
primer sets were found to have acceptable efficiencies between 90% and 120%, e.g., calculated efficiencies for Class 1 Ea and Eb correspond to
percentages of 106 and 101 (SYBR and SYBR1), whereas for IGF-1Ea, IGF-1Eb and Ec peptide to 90, 119 and 100, respectively (SYBR2-4) (A).
Following melting curve analysis, qRT-PCR products (e.g., Ec peptide) were further verified by gel electrophoresis, where only one band was observed
corresponding to the predicted length (B). The possibility of potentially contaminating DNA amplification was checked in a boosted PCR of 45
cycles using the designed primers (e.g., IGF-1Ea, IGF-1Eb, Ec peptide) or the primers used for amplification of β-actin, which served as internal
control for transcripts quantification and 300 ng of genomic DNA as a template. Products were analyzed electrophoreticaly, where no bands were
observed, using as positive control cyclophilin. (C). qRT-PCR: Quantitative real-time-polymerase chain reaction.
LnCap, were found to have elevated levels of both IGF-1Eaand IGF-1Eb isoforms, compared to others. The Ec peptidewas also found at maximum levels in KLE cells, with LnCapfollowing, whereas MCF7 cells presented the lowestexpression compared to the rest of tested cell lines. All threeisoforms were identified in both HLE-B3 and MG63 cellsunder control conditions, in contrast to previously reportedresults by our team under the particularly experimentalconditions (10, 13), probably due to the increased sensitivityof our new assay. Very interestingly, the IGF-1Eb isoformwas never identified in both estrogen receptor (ER)-positiveor -negative breast cancer cell lines MCF7 and MDA-MB-231, respectively, under our experimental conditions.
Identification of IGF-1 isoform origin; the prevalence of
class-1 peptides. We next wondered about the transcriptioninitiation sites of IGF-1 peptides located either on exon 1 or2 using specific primers, as described, for class 1 or 2
molecules, respectively. The levels of class 1 or 2 originatedpeptides are shown in Figure 4B and C, although for somecell lines amplification of classes’ transcripts was notpossible, probably due to the extended length of someamplicons. Most isoforms are found to be mainly and/orexclusively transcribed under the control of exon1 promoter,especially those regarding the IGF1-Eb and Ec peptide.Interestingly, IGF-1Ea and IGF-1Eb isoforms were found tobe strictly originated from exon 2 in HeLa and MG63 cells,respectively. Both promoters, located either to exon 1 or exon2, were found to contribute equally to the transcription of allthree isoforms in DLD-1 cells, whereas class 2 served as thepredominant origin for all three peptides only in KLE cells.
E2 and dexa modulated pro-IGF1-Ea and Eb expression in
PC3 cells. We have previously addressed the expressionpattern of pro-IGF1-Ea, -Eb and -Ec in PC3 cells undercontrol conditions (11). Since PC3 cells are androgen
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Figure 3. The melting curve analysis of the distinct IGF-1 transcripts. Following qRT-PCR’s last cycle (40), a melting curve analysis was generated
by the system’s software measuring SYBR green fluorescence throughout a temperature ramp from 65˚C to 95˚C. Analysis showed a unique curve
pick in specific for each transcript temperature, indicating the existence of a single product in each qRT-PCR reaction either for IGF-1Ea and IGF-
Eb isofroms (A, B) or Ec peptide (C), as well as for class 1 Ea, Eb and Ec peptide (D-F) or class 2 Ea, Eb and Ec peptide molecules (G-I). qRT-
PCR: Quantitative reverse transcription-polymerase chain reaction; IGF-1, insulin-like growth factor-1.
receptor-negative cells we tested the potentially hormonalregulation of IGF-1Ea, IGF-1Eb and Ec peptide expressionusing 10 or 100 nM E2 or Dexa for 24 or 48 h in PC3 cells.Indeed, the expression of IGF1-Ea and IGF-1Eb isoforms wassignificantly increased, namely Ea was up-regulated up to10-fold and Eb up to 4-fold, compared to control, by 10 nM E2after a 24-h exposure (p=0.025 and p=0.034, respectively),whereas 100 nM of Dexa for 48 h significantly decreased theIGF-1Ea and Eb expression (p=0.031 and p=0.042,
respectively). One hundred nM of E2 for 24 h or 10 nM ofDexa for 48 h slightly modulated Ea and Eb expression levelscompared to control. Since the last 24 aa of the carboxyl (-C) terminal of IGF-1Ec isoform have been suggested to havedistinct bioactive implications in prostate cancer (14), weanalyzed its regulation at the mRNA level in response toseveral factors in PC3 cells (Figure 4B). The majority of thesefactors (E2 or Dexa at 10 or 100 nM for 24 or 48 h)decreased the Ec peptide in all time and dose conditions
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Figure 4. Levels of distinct IGF-1 transcripts expression. Because greater Ct values correspond to smaller expression, levels of relative expression
were calculated after reversing the difference between the Ct of target gene and reference gene (β-actin) for each cell line (1/Dct). All samples were
measured in triplicates and the values were averaged, whereas Ct values above 35 were excluded from analysis. The comparison of IGF-1 variants’
expression between distinct cell lines revealed that the IGF-1Ea and Eb isoforms are expressed in greater levels in KLE, MEL28, DLD1 and LnCap
cells. Additionally, the Ec peptide was found at maximum levels also in KLE and LnCap, whereas MCF7 cells showed the lowest expression.
Interestingly, IGF-1Eb was completely lacking, under our experimental conditions, from both ER-positive or -negative MCF7 or MB231 breast
cancer cells (A). For the majority of cell lines used, we were able to determine the classes origin of IGF-1 transcripts. Class 1 proved as the
predominant origin of IGF-1 transcripts for most cell lines, especially for IGF-1Eb and Ec peptide variants (B), whereas, in some cases, exon 2
served as the only transcription initiation site (C). Ct, Threshold cycle; IGF-1, insulin-like growth factor-1.
tested. A significant reduction was observed after 10 or 100nM E2 for 24 h (p=0.048 and p=0.044, respectively) and 100nM Dexa after 48 h of exposure (p=0.032). An increase ofEc peptide expression was noticed by 10 nΜ of synthetic GHfor 48 h, however, not a significant one. For comparisonreasons and using the fold change formula, in all cases theexpression level of each IGF-1 isoform in PC3 cells undercontrol conditions served as fold 1.
Discussion
In this study we address, for the first time, the differentialexpression pattern of IGF-1 isoforms, including pro- , classesand E peptides, in a large number of human cancer cell linesunder control and treatment conditions using a novel qPCRassay. The distinct IGF-1 transcript patterns presented hereinraises the possibility for a unique role of each isoform,depending on cancer type.It has been long enough since the scientific communitystarted arguing about the existence and the biological activityof IGF-1 pro- and E peptides instead of the establishedmature IGF-1. Over the last years C-terminal E peptides haveproved a major point of argument regarding their biologicalroles, whereas pro-IGF-1 peptides present a higheracceptance among scientists for their pathophysiologicalactions, probably due to the fact that they contain the matureIGF-1 sequence. Among others, our team has previouslyaddressed unique roles for IGF-1 alternative transcripts,
especially for the Ec peptide, which notably has beensuggested to have IGF-1-independent actions (7-11). Uniqueroles have also been addressed, by independent teams, forIGF-1Ea, IGF-1Eb and IGF-1Ec isoforms in severalpathophysiological conditions, including cancer (15-24).These results, along with the data presented herein, furthersupport the notion for distinct roles of IGF-1 alternativetranscripts and implicate IGF-1 isoforms in human cancerbiology, in contrast to other studies suggesting a bioactivityonly for the mature IGF-1 (25, 26).The characterization of cells lines under controlconditions for IGF-1 transcripts revealed some noticeableresults. First, endometrial cancer KLE cells proved to havethe highest levels of IGF-1Ea and Ec peptide among all celllines tested. Although we have previously addressed thatKLE cells express all three pro-peptides (9), the directcomparison with the other cancer cells could raise thebiological significance of Ea and Ec peptide in endometrialmalignancy. Second, the complete lack, in our hands, ofIGF-1Eb peptide in breast cancer cell lines independently ofestrogen status in contrast to all other cell lines where wasindeed present, could reflect a unique and probablyprotective effect of this variant in breast cancer progression.Additionally, estrogen-sensitive MCF7 cells were found toexpress the minimum levels of Ec peptide. Except cancertype and estrogen status, many other factors could alsocontribute for the observed IGF-1 variant expressionpatterns, such as the existence of viral proteins (12). 
Christopoulos et al: IGF-1 Isoforms’ Expression in Cancer Cells
113
Figure 5. Hormonal regulation of IGF-1 transcripts in PC3 cells. Androgen receptor-negative prostate cancer PC3 cells were treated with 10 or 
100 nM of E2, Dexa or GH for 24 or 48 h of exposure, before harvesting of cells and RNA extraction. Control cells treated with placebos for 24 or
48 h, as appropriately, and levels of each IGF-1 transcript following qRT-PCR analysis served as fold 1. Results are presented as fold changes and
indicate a significant up-regulation of IGF-1Ea and IGF-1Eb isoforms by 10 nM E2 for 24 h (p=0.025 and p=0.034, respectively), whereas 100 nM
of Dexa for 48 h significantly reduced both (p=0.031 and p=0.042, respectively), when compared to control (A). The Ec peptide was negatively
regulated by the majority of treatment conditions used; 10 or 100 nM E2 for 24 h and 100 nM Dexa for 48 h significantly down-regulated the Ec
peptide (p=0.048, p=0.044 and p=0.032, respectively). A small induction in Ec peptide expression was observed only after addition of 10 nM GH
for 48 h (B). E2, Estradiol; Dexa, dexamethsone; GH, growth hormone; IGF-1, insulin-like growth factor-1; qRT-PCR: quantitative real-time-
polymerase chain reaction.
Very interestingly and for certain cell lines, we were ableto determine the transcription initiation site, located eitheron exon 1 or 2, for the expressed IGF-1 isoforms. Theimportance of this finding is fortified by the limitedknowledge on the potentially distinct roles of classes. Weaddress here that class 1 transcripts are predominant in thevast majority of the cell lines used. An explanation could bethe finding that class 1 transcripts may have highertranscription efficiencies, whereas class 2 transcripts couldbe more stable (27). Additionally, and pursuant to our results,showing a prevalence of transcripts containing exon 1, class2 peptides were suggested to have mainly endocrine actions,whereas class 1 mostly autocrine/paracrine ones (28). Class2 transcripts have been found to be predominant only in KLEcells. Taken together, the KLE cell line seems to present aunique pattern of IGF-1 isoforms raising, thus, the need forfurther studies in order to determine the importance of IGF-1 alternative transcripts in endometrial cancer pathology. Less is also known about the response of IGF-1 variants tohormonal treatments. For these experiments we usedandrogen receptor-negative prostate cancer cells (PC3), wherethe IGF-1 isoforms expression is well-addressed (11). Wefound a significant regulation (up or down) of pro peptides,Ea and Eb, depending on dose and time of E2 or Dexa used.Noticeable, the Ec peptide was down-regulated almost in allhormonal conditions tested, further supporting the notion fora distinct biological significance of this molecule in prostatecancer (11, 14). We found a small induction of Ec peptideexpression only after GH treatment in PC3 cells, although innormal human tissues, such as the skeletal muscle, the up-regulation at the mRNA level of all IGF-1 isoforms followingGH treatment was not evident (29).One limitation of our study is the difficulty to compare therelative expression of IGF-1 isoforms between so many celllines, using the fold change formula due to the differentialmolecular background represented by each one, as well asbetween the isoforms themselves due to the variantefficiency of the different pairs of primers used for eachtranscript (Figure 3A). For that reason we used the reversedDct formula (1/Dct) as a more suitable approach. We alsofailed to efficiently amplify class 1 or 2 transcripts in somecell lines probably because the length of class 1 and 2amplicons (Table I) were above the efficiency limits of theSYBR green assay, thus, a probes’ assay design couldprobably be proved more suitable for the distinctidentification of the IGF-1 classes. The disparities of theresults presented herein, for some cell lines compared toprevious published results by our team, could possibly beexplained by the increased sensitivity of our new assay.To conclude, this manuscript addresses the developmentof a specific, sensitive and cost effective tool for theidentification of almost all IGF-1 alternative transcripts. Thedifferential expression pattern in the cell lines used, which
served as models of several human malignancies, furtherimplicate the IGF-1 isoforms in human cancer biology. Theunique pattern, which was revealed for some cancer models,such as endometrial and breast malignancies, highlight theimportance of understanding the exact molecular function ofthe IGF-1 isoforms in these and other cancerous cases. Inaddition, our results may also contribute to the importanceand notion for a unique and distinct role of the Ec peptide.Further studies at the mRNA and protein level, as well asdetermination of IGF-1 isoforms’ bioactivities, are warrantedto confirm our findings and define the role of thesemolecules in cancer.
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